



**McBride, Domenica and ALHAZMI, Abdulfattah Yahya M and Laovitthayangoon, Sarunya and Boyd, Marie and Currie, Susan (2018) Parallel assessment of cell viability in cardiac and cancer cells following treatment with sunitinib. Heart, 104 (S4). ISSN 1468-201X , <http://dx.doi.org/10.1136/heartjnl-2018-SCF.16>**

This version is available at <https://strathprints.strath.ac.uk/63690/>

**Strathprints** is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<https://strathprints.strath.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: [strathprints@strath.ac.uk](mailto:strathprints@strath.ac.uk)

## Parallel assessment of cell viability in cardiac and cancer cells following treatment with sunitinib

Domenica McBride, Abdulfattah Alhazmi, Sarunya Laovitthayanggoon, Marie Boyd, Susan Currie

Strathclyde Institute of Pharmacy and Biomedical Sciences

University of Strathclyde

Various cardiopathological effects have been observed following chemotherapy treatment in cancer patients, due to anti-cancer drug-induced cardiotoxicity (CTX). A retrospective study of cancer survivors reported a 50% and 10% incidence of hypertension and heart failure respectively following treatment with the tyrosine kinase inhibitor sunitinib, licensed to treat pancreatic neuroendocrine tumours. The cellular mechanisms underlying CTX are not known. Here, for the first time, we compare the potency of sunitinib in both cardiac cells (primary cardiac fibroblasts (CFs)) and cancer cells (a pancreatic adenocarcinoma cell line (PANC-1)).

Adult rat CFs were isolated by bulk collagenase digestion, maintained in culture and used between passages 1–2. PANC-1 cells, from previously-frozen stocks, were used between passages 41–49. Cells were treated with sunitinib (0–10  $\mu\text{M}$  in CFs; 0–100  $\mu\text{M}$  in PANC-1) for 24 hour prior to epifluorescent imaging for phenotypic assessment. Cell viability was examined by alamar blue assays following 24 hour sunitinib treatment (0–100  $\mu\text{M}$ ).

Overall, results indicated increased sensitivity of CFs to sunitinib compared with PANC-1 cells. Phenotypic changes indicative of cell death, including appearance of intracellular vacuoles, were evident in CFs following 1  $\mu\text{M}$  sunitinib treatment whereas similar effects were not induced until 10  $\mu\text{M}$  treatment in PANC-1 cells. Alamar blue assays demonstrated a dramatic increase in CF death compared to PANC-1 death following treatment with 10  $\mu\text{M}$  sunitinib (11.6 $\pm$ 0.02 vs 56.5 $\pm$ 1.5 (% viability) CF vs PANC-1, n=3). A lower  $\text{IC}_{50}$  value for sunitinib was required to exert the same effects on CF ( $\text{IC}_{50}$ 5.2  $\mu\text{M}$ ) vs PANC-1 ( $\text{IC}_{50}$ 13.5  $\mu\text{M}$ ) cell viability.

These results suggest sunitinib can cause lethal effects in cardiac cells at lower doses than those required to induce pancreatic cancer cell death. Future work will aim to identify cellular mechanisms responsible for these toxic effects. Parallel studies in cardiac and cancer cells will be beneficial in distinguishing how focused anti-cancer drug delivery could be improved to avoid CTX.

Keywords: cardiac cells; sunitinib; cancer cells

Accepted manuscript of the following research output: McBride, D., ALHAZMI, A. Y. M., Laovitthayanggoon, S., Boyd, M., & Currie, S. (2018). Parallel assessment of cell viability in cardiac and cancer cells following treatment with sunitinib. *Heart*, 104(S4), [6]. DOI: [10.1136/heartjnl-2018-SCF.16](https://doi.org/10.1136/heartjnl-2018-SCF.16)